<DOC>
<DOCNO>EP-0617001</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Phenoxyphenylacetic acid derivatives
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P4300	C07D31764	A61P2900	A61P4300	A61K315375	A61K31165	A61P908	C07C31116	C07C6500	A61P900	C07C6524	A61K315375	C07C5900	C07C5970	A61P2900	C07D31900	A61P1302	A61K31535	C07D40500	C07D25704	C07D21536	C07D31700	A61K3147	C07D40900	C07C31151	A61P900	C07D40512	A61K31535	C07D31760	A61K31215	A61K3121	A61P1500	A61P912	A61K31357	C07D21500	C07D25700	C07D40912	A61K31357	A61P1100	A61P1100	C07D31918	A61P1300	A61P910	A61K31165	A61K3147	A61P1500	C07D29514	A61K31192	C07C31100	C07C5968	A61K3119	C07D29500	A61K3136	A61K31185	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07D	A61P	A61P	A61K	A61K	A61P	C07C	C07C	A61P	C07C	A61K	C07C	C07C	A61P	C07D	A61P	A61K	C07D	C07D	C07D	C07D	A61K	C07D	C07C	A61P	C07D	A61K	C07D	A61K	A61K	A61P	A61P	A61K	C07D	C07D	C07D	A61K	A61P	A61P	C07D	A61P	A61P	A61K	A61K	A61P	C07D	A61K	C07C	C07C	A61K	C07D	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P43	C07D317	A61P29	A61P43	A61K31	A61K31	A61P9	C07C311	C07C65	A61P9	C07C65	A61K31	C07C59	C07C59	A61P29	C07D319	A61P13	A61K31	C07D405	C07D257	C07D215	C07D317	A61K31	C07D409	C07C311	A61P9	C07D405	A61K31	C07D317	A61K31	A61K31	A61P15	A61P9	A61K31	C07D215	C07D257	C07D409	A61K31	A61P11	A61P11	C07D319	A61P13	A61P9	A61K31	A61K31	A61P15	C07D295	A61K31	C07C311	C07C59	A61K31	C07D295	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Phenoxyphenylacetic acids and derivatives of the general 
structural formula I 


have endothelin antagonist activity and are useful in treating 
cardiovascular disorders, such as hypertension, postischemic renal 

failure, vasospasm, cerebral and cardiac ischemia, myocardial 
infarction, endotoxic shock, benign prostatic hyperplasia, 

inflammatory diseases including Raynaud's disease and asthma. 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention is concerned with non-peptidic endothelin
receptor antagonists represented by the compound of Formula III,
pharmaceutical compositions containing these compounds, as well as
combination therapies which include a compound of the present
invention. The compounds of the present invention are therapeutic
agents particularly useful for the treatment of asthma, hypertension,
pulmonary hypertension, arteriosclerosis, congestive heart failure, renal
failure, particularly post-ischemic renal failure, cyclosporin
nephrotoxicity, vasospasm, vascular restenosis, cerebral and cardiac
ischemia and other ischemic states, myocardial infarction, Raynaud's
disease, benign prostatic hyperplasia, inflammatory bowel diseases,
including Crohn's disease and ulcerative colitis, as well as other
inflammatory diseases, or endotoxic shock caused by or associated with
endothelin.This invention further constitutes a method for
antagonizing endothelin receptors in a mammal, including humans,
which comprises administering to a mammal in need of such treatment
an effective amount of a compound of Formula III.Endothelin is a 21-amino acid peptide produced by
endothelial cells. The peptide is secreted not only by endothelial cells
but also by tracheal epithelial cells or from kidney cells. Endothelin
(ET-1) has a potent vasoconstrictor effect. The vasoconstricting effect 
is caused by the binding of endothelin to its receptor on the vascular
smooth muscle cells.1-3Endothelin-1 (ET-1) is one of three recently identified
potent vasoconstricting peptides which also includes endothelin-2 (ET-2)
and endothelin-3 (ET-3) whose sequences differ from ET-1 by two and
six amino acids, respectively.4Increased levels of endothelin are found in the blood of
patients with essential hypertension, acute myocardial infarction,
pulmonary hypertension, Raynaud's disease or atherosclerosis or in the
washing fluids of the respiratory tract of patients with asthma compared
to normal levels.5-8An experimental model of cerebral vasospasm and a second
model of acute renal failure have led to the conclusion that endothelin is
one of the mediators causing cerebral vasospasm following a
subarachnoid hemorrhage, and renal failure.9-10Endothelin was also found to control the release of many
physiological substances such as renin, atrial natriuretic peptide,
endothelium-derived relaxing factor (EDRF), thromboxane A2,14,
prostacyclin, norepinephrine, angiotensin II and substance P.11-16
Further, endothelin causes contraction of the smooth muscle of the
ga
</DESCRIPTION>
<CLAIMS>
A compound of structural formula III:


or a pharmaceutically acceptable salt thereof, wherein:

R
3a
 and R
3b
 are independently:

(a) H,
(b) F, Cl, Br, or I,
(c) -NO
2
,
(d) (C
1
-C
6
)-alkyl,
(e) -OR
7
,
(f) -NHCO-(C
1
-C
4
)-alkyl,
(g) -NHCO-O(C
1
-C
4
)-alkyl,
(h) -O-(CH
2
)m-OR
7
,
(i) -CONR
7
R
11
, or
(j) -COOR
7
;
R
1
 and R
2
 on adjacent carbon atoms are joined together to
form a ring structure:


A represents:

a) -Y-[C(R
6
)(R
6
)]s -Y-, or
b) -C(R
4
)=C(R
5
)-C(R
4
)=C(R
5
)-;
m is 2, 3 or 4,
n is 0, 1 or 2,
s is 1 or 2,
Y is -O-, -S- and NR
7
R
4
 and R
5
 are independently:

(a) H,
(b) (C
1
-C
6
)-alkyl,
(c) (C
3
-C
7
)-cycloalkyl,
(d) F, Cl, Br, I,
(e) -NR
7
COOR
11
,
(f) -SO
2
NR
7
R
11
,
(g) -O-(C
1
-C
4
)-alkyl,
(h) -S(O)
n
-(C
1
-C
4
)-alkyl, or
(i) -NHSO
2
R
11
;
R
6
 is:

(a) H, or
(b) (C
1
-C
4
)-alkyl;
R
7
 is:

(a) H,
(b) (C
1
-C
6
)-alkyl,
(c) phenyl, or
(d) benzyl;
R
9
 and R
10
 are independently:

(a) H,
(b) (C
1
-C
6
)-alkyl, unsubstituted or substituted with
(C
3
-C
7
)-cycloalkyl,
(c) Cl, Br, F, I,
(d) (C
1
-C
6
)-alkoxy, or
(e) hydroxy-(C
1
-C
6
)-alkyl;
R
11
 is

(a) (C
1
-C
6
)-alkyl, unsubstituted or substituted with a
substituent selected from the group consisting of:


i) -OR
7
,
ii) -N[R
7
]
2
,
iii) -NH
2
,
iv) -COOR
7
, or
v) -N[CH
2
CH
2
]
2
Q;
(b) aryl, wherein aryl is defined as phenyl or
naphthyl which is unsubstituted or substituted with 

one or two substituents selected from the group
consisting of:


i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CO[NR
7
]
2
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NH
2
,
vii) -NH[(C
1
-C
4
)-alkyl],
viii) -N[(C
1
-C
4
)-alkyl]
2
, or
ix) -CON[CH
2
CH
2
]
2
Q;
(c) -(C
1
-C
4
)-alkylaryl, wherein aryl is as defined
above,
(d) (C
3
-C
7
)-cycloalkyl,
(e)

R
7
 and R
11
 on the same nitrogen atom they can join together to
form a ring selected from the group consisting of:

morpholinyl, piperazinyl, or pyrrolyl, or
Q is O, S or -NR
7
;
R
12
 is

(a) H,
(b) (C
1
-C
6
)-alkyl, wherein alkyl is defined as
unsubstituted or substituted with one or two

substituents selected from the group consisting of:

i) -OH,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -O-(C
1
-C
4
)-cycloalkyl,
iv) -S(O)
n
-(C
1
-C
4
)-alkyl,
iv) -NR
7
-(C
1
-C
4
)-alkyl, 
v) -NR
7
R
11
,
vi) -COOR
7
,
vii) -CONHR
7
,
viii) -OCOR
11
,
ix) -CONR
7
R
11
,
x) -NR
7
CONR
7
R
11
,
xi) -NR
7
COOR
11
,
xii) -C(R
6
)(OH)-C(R
6
)(R
7
)(OH), or
xiii) -SO
2
NR
7
R
11
,
(c) -COOR
7
,
(d) -CONH
2
,
(e) -CONR
7
R
11
,
(f) -CONR
7
CO
2
R
7
,
(g) -C(R
6
)(OH)-C(R
6
)(R
7
)(OH), or
(h) -CONHSO
2
R
11
,
(i) -SO
2
NR
7
R
11
,
(j) -NR
7
SO
2
NR
7
R
11
,
(k) -CO-amino acid, wherein amino acid is defined as
an L-or D- amino acid selected from the group

consisting of Ala, Ile, Phe, Asp, Pro and Val and
which can be further substituted as a (C
1
-C
6
)-alkyl
ester or an amide, or
(l)

X is
-O-;
Z is:

(a) -CO
2
H, 
(b) -CO
2
R
13
,
(c) -CONH-(tetrazol-5-yl),
(d) -CONHSO
2
-aryl, wherein aryl is defined as
phenyl or naphthyl which is unsubstituted or

substituted with one or two substituents selected
from the group consisting of:


i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CONR
7
R
11
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NH
2
,
vii) -NH[(C
1
-C
4
)-alkyl],
viii) -N[(C
1
-C
4
)-alkyl]
2
, or
ix) -phenyl;
(e) -CONHSO
2
-(C
1
-C
8
)-alkyl, wherein alkyl is
unsubstituted or substituted as defined in R
4
(b),
(f) -CONHSO
2
-heteroaryl, wherein heteroaryl is
defined as carbazolyl, furyl, thienyl, pyrrolyl,

isothiazolyl, imidazolyl, isoxazolyl, thiazolyl,
oxazolyl, pyrazolyl, pyrazinyl, pyridyl,

pyrimidyl, purinyl, or quinolinyl, which is
unsubstituted or substituted with one or two

substituents selected from the group consisting of:

i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CONR
7
R
11
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NR
7
CONR
7
R
11
, and
vii) -NR
7
COOR
11
;
(g) -tetrazol-5-yl; and
R
13
 is: (C
1
-C
4
)-alkyl.
A compound according to claim 1 of structural formula IV:


or a pharmaceutically acceptable salt thereof, wherein:

R
1
 and R
2
 taken together form the ring structure:

A represents:

a) -Y-[C(R
6
)(R
6
)]
S
 -Y-, or
b) -C(R
4
)=C(R
5
)-C(R
4
)=C(R
5
)-;
s is 1 or 2;
Y is -O-;
R
3a
 is:

(a) H,
(b) F, Cl, Br, or I,
(c) (C
1
-C
6
)-alkyl,
(d) -OR
7
, 
(e) -O-(CH
2
)m-OR
7
,
(f) -CONR
7
R
11
, or
(g) -COOR
7
;
m is 2, 3 or 4;
R
4
 and R
5
 are independently:

(a) H,
(b) (C
1
-C
6
)-alkyl,
(c) (C
3
-C
7
)-cycloalkyl,
(d) F, Cl, Br, I,
(e) -NR
7
COOR
11
,
(f) -SO
2
NR
7
R
11
,
(g) -O-(C
1
-C
4
)-alkyl,
(h) -S(O)
n
-(C
1
-C
4
)-alkyl, or
(i) -NHSO
2
R
11
;
n is 0, 1 or 2,
R
6
 is:

(a) H, or
(b) (C
1
-C
4
)-alkyl;
R
7
 is:

(a) H,
(b) (C
1
-C
6
)-alkyl,
(c) phenyl, or
(d) benzyl;
R
9
 is:

(a) H,
(b) (C
1
-C
6
)-alkyl, unsubstituted or substituted with
(C
3
-C
7
)-cycloalkyl,
(c) Cl, Br, F, I,
(d) (C
1
-C
6
)-alkoxy, or
(e) hydroxy-(C
1
-C
6
)-alkyl;
R
11
 is

(a) (C
1
-C
6
)-alkyl, unsubstituted or substituted with a
substituent selected from the group consisting of:


i) -OR
7
,
ii) -N[R
7
]
2
,
iii) -NH
2
,
iv) -COOR
7
, or
v) -N[CH
2
CH
2
]
2
Q;
(b) aryl, wherein aryl is defined as phenyl or
naphthyl which is unsubstituted or substituted with

one or two substituents selected from the group
consisting of:


i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CO[NR
7
]
2
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NH
2
,
vii) -NH[(C
1
-C
4
)-alkyl],
viii) -N[(C
1
-C
4
)-alkyl]
2
, or
ix) -CON[CH
2
CH
2
]
2
Q;
(c) -(C
1
-C
4
)-alkylaryl, wherein aryl is as defined
above,
(d) (C
3
-C
7
)-cycloalkyl, 
(e)

R
7
 and R
11
 on the same nitrogen atom they can join together to
form a ring selected from the group consisting of:

morpholinyl, piperazinyl, or pyrrolyl, or
Q is O, S or -NR
7
;
R
12
 is

(a) H,
(b) (C
1
-C
6
)-alkyl, wherein alkyl is defined as
unsubstituted or substituted with one or two

substituents selected from the group consisting of:

i) -OH,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -O-(C
1
-C
4
)-cycloalkyl,
iv) -S(O)
n
-(C
1
-C
4
)-alkyl,
iv) -NR
7
-(C
1
-C
4
)-alkyl,
v) -NR
7
R
11
,
vi) -COOR
7
,
vii) -CONHR
7
,
viii) -OCOR
11
,
ix) -CONR
7
R
11
,
x) -NR
7
CONR
7
R
11
,
xi) -NR
7
COOR
11
,
xii) -C(R
6
)(OH)-C(R
6
)(R
7
)(OH), or
xiii) -SO
2
NR
7
R
11
,
(c) -COOR
7
,
(d) -CONH
2
,
(e) -CONR
7
R
11
,
(f) -CONR
7
CO
2
R
7
,
(g) -C(R
6
)(OH)-C(R
6
)(R
7
)(OH), or 
(h) -CONHSO
2
R
11
,
(i) -SO
2
NR
7
R
11
,
(j) -NR
7
SO
2
NR
7
R
11
,
(k) -CO-amino acid, wherein amino acid is defined as
an L-or D- amino acid selected from the group

consisting of Ala, Ile, Phe, Asp, Pro and Val and
which can be further substituted as a (C
1
-C
6
)-alkyl
ester or an amide, or
(l)

X is

(a) -O-,
(b) -NR
7
-, or
(c) -single bond;
Z is:

(a) -CO
2
H,
(b) -CO
2
R
13
,
(c) -CONH-(tetrazol-5-yl),
(d) -CONHSO
2
-aryl, wherein aryl is defined as
phenyl or naphthyl which is unsubstituted or

substituted with one or two substituents selected
from the group consisting of:


i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CONR
7
R
11
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NH
2
,
vii) -NH[(C
1
-C
4
)-alkyl],
viii) -N[(C
1
-C
4
)-alkyl]
2
, or 
ix) -phenyl;
(e) -CONHSO
2
-(C
1
-C
8
)-alkyl, wherein alkyl is
unsubstituted or substituted as defined in R
4
(b),
(f) -CONHSO
2
-heteroaryl, wherein heteroaryl is
defined as carbazolyl, furyl, thienyl, pyrrolyl,

isothiazolyl, imidazolyl, isoxazolyl, thiazolyl,
oxazolyl, pyrazolyl, pyrazinyl, pyridyl,

pyrimidyl, purinyl, or quinolinyl, which is
unsubstituted or substituted with one or two

substituents selected from the group consisting of:

i) (C
1
-C
4
)-alkyl,
ii) -O-(C
1
-C
4
)-alkyl,
iii) -CONR
7
R
11
,
iv) F, Cl, Br or I,
v) -COOR
7
,
vi) -NR
7
CONR
7
R
11
, and
vii) -NR
7
COOR
11
, or
(g) -tetrazol-5-yl; and
R
13
 is: (C
1
-C
4
)-alkyl.
A compound according to claim 1 selected from the group
consisting of:


2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-ethylenedioxyphenyl)acetic

acid; 
2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(3,4-methylenedioxyphenyl)acetic

acid;
2-[(2,6-dipropyl-4-hydroxymethyl)phenoxy]-2-(2-naphthyl)acetic acid;
2-[(2,6-dipropyl-4-(2-hydroxyethyl)phenoxy]-2-(2-naphthyl)acetic acid;
2-[(2,6-dipropyl-4-(2-hydroxyethyl)phenoxy]-2-(3,4-methylenedioxyphenyl)acetic

acid;
2-[(2,6-dipropyl-4(1,2-dihydroxyethyl)phenoxy)]-2-(2-naphthyl)acetic

acid;
2-[(2,6-dipropyl-4-(1-hydroxypentyl)phenoxy]-2-(2-naphthyl)acetic

acid;
2-[(4-carboxy-2,6-dipropyl)phenoxy]-2-[3,4-methylenedioxyphenyl]

acetic acid;
(N-4-t-butylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(benzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-phenylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propyl-phenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-chlorobenzenesulfonyl)-2-(4-methoxycarbonyl-2-propyl-phenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-methylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propyl-phenoxy)-2-(3,4-methylenedioxyphenyl)acetamide; 
N-(5-iso-butylthien-2-ylsulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-methoxybenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-dimethylaminobenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(2-methylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(2-methoxycarbonylbenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(2-chlorobenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(3-chlorobenzenesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(dansylsulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(8-quinolinesulfonyl)-2-(4-methoxycarbonyl-2-propylphenoxy)-2-(3,4-methylenedioxyphenylacetamide;
N-(4-t-butylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide; 
N-(benzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-phenylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-chlorobenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-methylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(5-isobutylthien-2-ylsulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-methoxybenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(4-dimethylaminobenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-3,4-methylenedioxyphenyl)acetamide;
N-(2-methylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(2-methoxycarbonylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(2-chlorobenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
N-(3-chlorobenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide; 
N-(dansylsulfonyl)-2-(4-carboxy-2-propylphenoxy)-3,4-methylenedioxyphenyl)acetamide;
N-(8-quinolinesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenylacetamide;
N-(8-quinolinesulfonyl)-2-(4-carboxamido-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
α-(4-carbomethoxy-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetic
acid;
N
-(4-
iso
-propylbenzenesulfonyl)-α-(4-carbomethoxy-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetamide;
N
-(4-
iso
-propylbenzenesulfonyl)-α-(4-carboxy-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetamide
dipotassium salt;
α-(2-
iso
-butyl-4-carbomethoxyphenoxy)-3,4-methylenedioxyphenylacetic
acid;
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
iso
-butyl-4-carbomethoxyphenoxy)-3,4-methylenedioxyphenylacetamide;
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
iso
-butyl-4-carboxyphenoxy)-3,4-methylenedioxyphenylacetamide;
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
n
-propyl-4-carboxamidophenoxy)-3,4-methylenedioxyphenylacetamide; 
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
n
-propyl-4-hydroxymethylphenoxy)-3,4-methylenedioxyphenylacetamide;
α-(2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetic acid
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetamide;
α-(4-hydroxymethyl-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetic
acid;
α-(4-(2-hydroxyethyl)-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetic
acid; 
N
-(4-
iso
-propylbenzenesulfonyl)-2-(4-carbomethoxy-2-
n
-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(4-
iso
-propylbenzenesulfonyl)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-carboxamido-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-methylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-2-hydroxyethylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-morpholinylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-3-methylbutylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-carboxymethylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(L-Ala-OEt)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide; 
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-2-ethoxycarbonylethyl-carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(L-Ala)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-2-carboxyethylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-3-hydroxypropyl-carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-tetrazol-5-ylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-3-(morpholin-4-yl)propylcarboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(D-Ala-OMe)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(D-Ala)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(3-carboxymethylpropyl)carboxamido)-2-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide;
N-(4-
iso
-propylbenzenesulfonyl)-2-(4-(N-(3-carboxypropyl)carboxamido)-2-
n
-propylphenoxy)-2-(5-methoxy-3,4-methylenedioxyphenyl)acetamide; 
α-(2-
n
-propyl-4-methylaminosulfonylphenoxy)-3,4-methylenedioxyphenylacetic
acid; and
N
-(4-
iso
-propylbenzenesulfonyl)-α-(2-
n
-propyl-4-methylaminosulfonylphenoxy)-3,4-methylenedioxyphenylacetamide
potassium salt.
A compound according to claim 1 selected from the group
consisting of:


N
-(4-
iso
-propylbenzenesulfonyl)-α-(4-carboxy-2-
n
-propylphenoxy)-3,4-methylenedioxyphenylacetamide
dipotassium salt;
N-(8-quinolinesulfonyl)-2-(4-carboxy-2-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide;
and
N-(4-dimethylaminobenzenesulfonyl)-2-(4-carboxy-2-
n
-propylphenoxy)-2-(3,4-methylenedioxyphenyl)acetamide,
or a

pharmaceutically acceptable salt.
A pharmaceutical composition comprising a therapeutically
effective amount of a compound as defined in any one of Claims 1 to 4 or a

pharmaceutically acceptable salt thereof and a pharmaceutically
acceptable carrier.
A compound as defined in any one or claims 1 to 4 or a
pharmaceutically acceptable salt thereof, for use in a method of treatment

of the human or animal body.
A compound according to Claim 6 for use in the treatment of
hypertension.
Use of a compound as defined in any of Claims 1 to 4 or a
pharmaceutically acceptable salt thereof, for the

manufacture of a medicament for the treatment of a
condition selected from the group consisting of:

hypertension, pulmonary hypertension, Raynaud's disease,
myocardial infarction, angina pectoris, congestive heart

failure, acute renal failure, cerebral infarction,
cerebral vasospasm, arteriosclerosis, vascular

restenosis, asthma, benign prostatic hyperplasia,
inflammatory bowel diseases, endotoxic shock, endotoxin-induced

multiple organ failure or disseminated
intravascular coagulation, or cyclosporin-induced renal

failure or hypertension in a mammal. 
The composition according to Claim 5 which includes another
antihypertensive agent selected from: A2-adrenosine receptor agonists,

α-adrenergic antagonists, angiotensin II antagonists, angiotensin
converting enzyme inhibitors, β-adrenergic antagonists, atriopeptidase

inhibitors(alone or with ANP), calcium channel blockers, diuretics,
potassium channel agonists, renin inhibitors, sertonin antagonists,

sympatholytic agents, and other antihypertensive agents, which are
members selected from the group consisting of:


A-69729, FK 906, FK 744, UK-73900, CSG 22492C, amiloride,
atenolol, atriopeptin, bendroflumethiazide, chlorothalidone,

chlorothiazide, clonidine, cromakalin, cryptenamine acetates and
cryptenamine tannates, deserpidine, diazoxide, doxazosin, guanabenz,

guanethidine, guanethidine sulfate, hydralazine hydrochloride,
hydrochlorothiazide, isradipine, ketanserin, losartan, metolazone,

metoprolol, metoprolol tartate, methyclothiazide, methyldopa,
methyldopate hydrochloride, minoxidil, nadolol, pargyline

hydrochloride, pinacidil, pindolol, polythiazide, prazosin,
propranolol, 
rauwolfia
serpentina
, rescinnamine, reserpine, sodium
nitroprusside, spironolactone, terazosin, timolol maleate,

trichlormethiazide, trimethophan camsylate, verapamil, benzthiazide,
quinethazone, ticrynafan, triamterene, acetazolamide, aminophylline,

cyclothiazide, ethacrynic acid, furosemide, merethoxylline procaine,
sodium ethacrynate, captopril, delapril hydrochloride, enalapril,

enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril.
quinapril hydrochloride, ramapril, teprotide, zofenopril, zofenopril

calcium, diflusinal, diltiazem, felodipine, nicardipine, nifedipine,
niludipine, nimodipine, nisoldipine, nitrendipine.
</CLAIMS>
</TEXT>
</DOC>
